Quarterly report · Q3
3341.TEDINET S100SVMG
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥254.1bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥313.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥232.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥6.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥5.8bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.8bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥6.5bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥7.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.8bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.8bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥194.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥185.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥187.6bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥134.9bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥128.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.5bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥56.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥56.3bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥125.99 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.55 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.92 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥143.23 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.6% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥10.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥10.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥5.4bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥225.6bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥225.6bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥7.4bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥7.3bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥35m |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥795m |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥31.2bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥21.2bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥9.9bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥555m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥264.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥254.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥12.0bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥10.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥10.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥4.9bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥208.1bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥208.1bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2m |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10m |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥602m |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥29.3bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥18.9bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.4bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥456m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥243.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥232.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥10.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 356
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)桃木 秀一 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)佐野 明宏 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 232844000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 254127000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 313318000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 5836000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 6517000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 7682000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 4289000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 3769000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 4458000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 4300000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 3773000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 4456000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 56327000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 59511000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 56483000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 187619000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 194365000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 185297000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 143.23 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 125.99 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 148.92 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.3002 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.3062 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.3048 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 89.64 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 67.55 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 32048000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 32048000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 32048000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 32048000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 2061600 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 29923800 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 299238 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 62600 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 32048000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 299238 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 2061600 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |